ReviewCurrent atherosclerosis reports2025
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease.
Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- [Determination of 30 homologues of phosphatidylcholines and lysophosphatidylcholines in human serum by liquid chromatography-tandem mass spectrometry and their correlation analysis with coronary artery disease].Se pu = Chinese journal of chromatography · 2026Article
- Metabolomic Markers of Left Ventricular Structure, Diastolic Function, and Risk of Coronary Heart Disease: A Longitudinal Study in American Indian Individuals.Journal of the American Heart Association · 2026Article
- Remodeling the gut-heart axis: Danggui Sini granule mitigates vasospastic coronary heart disease via microbiota-metabolite interactions.Frontiers in cardiovascular medicine · 2026Article
- Investigating key genes and molecular mechanisms of prostate cancer and coronary heart disease through transcriptomics and experimental validation.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purpose of reviewCoronary heart disease (CHD) is a major global threat to human health. This review summarizes the latest progress of metabolomics in CHD research, and provides insights into the pathogenesis and identify dependable biomarkers of CHD. RECENT
findingsThis review has summarized 303 metabolic indicators related to CHD, with a focus on 53 biomarkers, and highlighted the top 10 biomarkers with significant clinical value. The biosynthesis of unsaturated fatty acids, amino acids, and aminoacyl-tRNA, as well as amino acid metabolism, are linked to CHD pathogenesis. Amino acids and lipids play essential roles in understanding the onset and progression of CHD. This review provides a new perspective on enhancing our understanding of CHD pathogenesis and developing effective treatment interventions.
Indexed as
Identifiers
40488965What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.